Bioventus launched DUROLANE® single-injection joint fluid osteoarthritis (OA) therapy in Malaysia, through exclusive distribution partner Athrotech.
The company cited estimates of 20% of the adult Malaysian population has OA, noting that knee OA is the most common form. Further, the market exhibits a favorable mix of private, payor and self-pay patients.
This is the fourth market in Asia that Bioventus has entered with DUROLANE.
Bioventus launched DUROLANE® single-injection joint fluid osteoarthritis (OA) therapy in Malaysia, through exclusive distribution partner Athrotech.
The company cited estimates of 20% of the adult Malaysian population has OA, noting that knee OA is the most common form. Further, the market exhibits a favorable mix...
Bioventus launched DUROLANE® single-injection joint fluid osteoarthritis (OA) therapy in Malaysia, through exclusive distribution partner Athrotech.
The company cited estimates of 20% of the adult Malaysian population has OA, noting that knee OA is the most common form. Further, the market exhibits a favorable mix of private, payor and self-pay patients.
This is the fourth market in Asia that Bioventus has entered with DUROLANE.
Copy to clipboard 
